For patients with locally advanced cervical adenocarcinoma and adenosquamous carcinoma treated with CRT, the underexpression of PD-L1 was a prognostic factor for tumor relapse (p = 0.041), indicating that PD-L1 expression might be a novel biomarker for CRT outcome (Lai et al., 2017). Here, CD274 is linked to adenosquamous carcinoma.